News

The European Commission (EC) will now review the recommendation. On receiving approval, this would represent the third authorised indication for the therapy in the EU. Approved in the

Lecanemab is an investigational anti-amyloid beta (Aβ) protofibril antibody intended to treat AD with confirmed amyloid pathology. On 6 January, it received accelerated approval from the US Food

The funding round has seen participation of current investors Boehringer Ingelheim Venture Fund, M. Ventures, PMV, Gemma Frisius Fonds, and CD3/ KU Leuven. As part of the investment,

Under the terms of the partnership deal between the companies, Hyloris will receive a share on any revenues related to product, such as royalties, license fees, milestone payments,

Serving as the primary IND for TScan’s solid tumour programme, T-Plex will enable customised combinations of T cell receptor (TCR)-engineered T cell therapies (TCR-T) to be given to

MFDS concluded that GX-188E met the criteria for this designation after assessing the complete set of Phase II results from the clinical trial that was recently completed in

In December last year, Evaxion secured the FDA approval to advance with its Phase IIb clinical trial, where EVX-01 is given along with KEYTRUDA to patients with metastatic

The recombinant adeno-associated virus (rAAV)-based gene therapy is being studied to treat neovascular Age Related Macular Degeneration (nAMD), which causes severe loss of vision and irreversible blindness across

The adeno-associated viral serotype rh10 (AAVrh10) gene therapy FBX-101 is delivered intravenously after hematopoetic stem cell transplant (HSCT) infusion. The designation for this lead adeno-associated virus (AAV) drug